Patent · US Active

Substituted [1,2,4]triazolo[1,5-a]pyrazines as phosphodiesterase inhibitors

US9994590B2 · kind B2 · utility

0Cited by

0References

25Claims

0Family size

Assignee

Sunovion Pharmaceuticals Inc. · US

Inventors

John Emmerson Campbell · Cambridge, US
Philip Glyn Jones · Danvers, US
Scott Malcolm · Southborough, US

Key dates

Filing date	Oct 20, 2016
Grant date	Jun 12, 2018
Priority date	—
Expiry date	Oct 20, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D487/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Provided herein are substituted [1,2,4]triazlolo[1,5-α]pyrazine compounds, and pharmaceutical compositions thereof, useful for the treatment of, for example, central nervous system and metabolic diseases and disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.